The purpose of this study is to evaluate the immunogenicity and safety of three consecutive lots of bivalent HPV (Type 16,18) vaccine (Pichia pastoris) in healthy female subjects aged 9 - 30 years, and demonstrate the non-inferiority of the candidate HPV vaccine manufactured at commercial scale compared with a pilot scale.

Inclusion Criteria:

• 9-30 healthy female able to provide legal identification.
• Written informed consent had to be obtained from the subject prior to enrolment (for subjects below the legal age of consent, written informed consent had to be obtained from a parent or legal guardian of the subject and, in addition, the subject had to sign and personally date a written informed assent).
• Women of child-bearing age(WOCBA): Subject had to have a negative urine pregnancy test, no plan to be pregnant in 7 months, and agree to use adequate contraceptive precautions during study period.

Exclusion Criteria:

• Subject has received a marketed HPV vaccine or participated in an HPV vaccine clinical trial.
• History of abnormal cervical screen test result (ASC-US or worse) or history of genital warts.
• History of severe allergic reaction that required medical intervention.
• History of allergic disease or reactions likely to be exacerbated by any component of the study vaccines.
• Pregnant or breastfeeding, or within 6 weeks after the end of pregnancy.
• Fever prior to vaccination (auxiliary temperature ≥37.3 °C).
• Hypertension (physical examination systolic blood pressure 140mmHg and or diastolic blood pressure 90mmHg.
• Received live attenuated vaccine within 15 days before vaccination or subunit or inactivated vaccine within 7 days.
• Received immunoglobulin and/or blood product 3 months prior to the first vaccination.
• Acute diseases or acute stage of the chronic diseases within 3 days preceding the vaccination.
• According to the judgment of the investigator, subject has or had any other symptoms, medical history and other factors that are not suitable for participating in this clinical trial.